We have added a new TMS device at our Cherry Hill Office: Brainsway Deep TMS. Deep TMS (dTMS) is a new technology that produces significantly deeper cortical stimulation. Brainsway Deep TMS is approved by the FDA for Major Depressive Disorder. The FDA indication is based on a 16-week double-blind, placebo-controlled multi-center study, which enrolled over 200 subjects, showing a profound decline in the Hamilton Depression Rating Scale (HDRS-21), a significant remission rate of 32.6% and an even higher response rate in treatment resistant patients. Brainsway Deep TMS is currently being studied in over 60 clinical trials at leading institutions worldwide. Approved clinical indications in Europe include Bipolar Disorder, PTSD, Schizophrenia (negative symptoms), Autism, Alzheimer’s disease, Parkinson’s disease, chronic pain and smoking cessation.
We are pleased to introduce Suzanne Kerns, M.D., who joined SeattleNTC in August 2014. Dr. Kerns completed her undergraduate studies at the University of North Carolina in Chapel Hill. She attended medical school at the University of Sydney, Australia, followed by psychiatry residency at Duke University. Dr. Kerns subsequently completed a Fellowship in Brain Stimulation at Medical University of South Carolina under the guidance of Mark S. George MD, a founding father of transcranial magnetic stimulation (TMS). Special clinical interests include women’s mental health, post-traumatic stress disorders and addiction disorders—and especially the developing applications for brain stimulation in these areas.